首页|不同剂量替罗非班在高龄老年急性STEMI患者急诊PCI中的应用效果分析

不同剂量替罗非班在高龄老年急性STEMI患者急诊PCI中的应用效果分析

扫码查看
目的 探讨不同剂量替罗非班在高龄老年急性ST段抬高型心肌梗死(STEMI)患者急诊经皮冠状动脉(冠脉)介入治疗(PCI)中的应用效果.方法 选取 100 例行急诊PCI的高龄老年急性STEMI患者进行研究,依照随机分组法将患者分为参照组和研究组,每组 50 例.参照组采用标准剂量替罗非班[术中、术后 36 h持续进行 0.15 μg/(kg·min)泵入]治疗,研究组采用 1/2 剂量替罗非班[术中、术后 36 h持续进行 0.075 μg/(kg·min)泵入]治疗.比较两组治疗后心肌灌注水平、心肌损伤情况及不良心血管事件(MACE)发生情况.结果 研究组MACE发生率 4.00%(2/50)显著低于参照组的 16.00%(8/50)(χ2=4.000,P=0.046<0.05).研究组治疗前肌钙蛋白T(cTnT)(5.23±0.49)µg/L、肌酸激酶同工酶(CK-MB)(110.66±13.26)U/L、心型脂肪酸结合蛋白(hFABP)(11.46±1.68)ng/ml,治疗后分别为(1.89±0.64)µg/L、(64.97±5.56)U/L、(4.21±0.39)ng/ml;参照组治疗前cTnT(5.20±0.37)µg/L、CK-MB(111.61±11.64)U/L、hFABP(12.06±1.49)ng/ml,治疗后分别为(1.92±0.57)µg/L、(65.71±6.29)U/L、(4.31±0.44)ng/ml.两组治疗后cTnT、CK-MB、hFABP水平均低于治疗前(P<0.05),两组组间cTnT、CK-MB、hFABP水平无显著差异(P>0.05).两组术后心肌梗死溶栓试验(TIMI)血流分级、校正TIMI帧数(CTFC)、慢血流(SCF)发生率、ST段回落率比较无差异(P>0.05).结论 标准剂量与 1/2 剂量替罗非班在高龄老年急性STEMI患者急诊PCI中改善患者心肌灌注水平与心肌损伤效果相当,但1/2剂量替罗非班使用剂量可减少患者MACE发生率,具有一定临床意义.
Effect analysis of different doses of tirofiban in emergency PCI in elderly patients with acute STEMI
Objective To investigate the practical effect of different doses of tirofiban in emergency percutaneous coronary intervention(PCI)in elderly patients with acute ST elevation myocardial infarction(STEMI).Methods 100 elderly patients with acute STEMI who underwent emergency PCI were selected for this study,and the patients were randomly divided into a reference group and a study group,with 50 cases in each group.The reference group was treated with standard dose of tirofiban[0.15 μg/(kg·min)pumped continuously intraoperatively and 36 h postoperatively],while the study group was treated with 1/2 dose of tirofiban[0.075 μg/(kg·min)pumped continuously intraoperatively and 36 h postoperatively].The myocardial perfusion level,myocardial injury and major adverse cardiovascular events(MACE)were compared between the two groups after treatment.Results The MACE incidence rate of 4.00%(2/50)in the study group was significantly lower than that of 16.00%(8/50)in the reference group(χ2=4.000,P=0.046<0.05).In the study group,the troponin T(cTnT),creatine kinase isoenzyme(CK-MB)and heart fatty acid-binding protein(hFABP)were(5.23±0.49)µg/L,(110.66±13.26)U/L and(11.46±1.68)ng/ml before treatment,and(1.89±0.64)µg/L,(64.97±5.56)U/L and(4.21±0.39)ng/ml after treatment,respectively.In the reference group,cTnT,CK-MB and hFABP were(5.20±0.37)µg/L,(111.61±11.64)U/L and(12.06±1.49)ng/ml before treatment,and(1.92±0.57)µg/L,(65.71±6.29)U/L and(4.31±0.44)ng/ml after treatment,respectively.The levels of cTnT,CK-MB and hFABP in both groups after treatment were lower than those before treatment(P<0.05).There were no significant differences in cTnT,CK-MB and hFABP levels between the two groups(P>0.05).After treatment,there were no differences in thrombolysis in myocardial infarction(TIMI)blood flow classification,corrected TIMI frame count(CTFC),incidence of slow coronary flow(SCF)and ST segment depression between the two groups(P>0.05).Conclusion Standard dose and 1/2 dose of tirofiban have similar effects on improving myocardial perfusion and myocardial injury in elderly acute STEMI patients undergoing emergency PCI.However,the use of 1/2 dose tirofiban can reduce the incidence of MACE in patients and has certain clinical significance.

TirofibanAcute ST elevation myocardial infarctionPercutaneous coronary intervention therapyMyocardial perfusionMyocardial injury

徐增政、高亚平

展开 >

274300 单县中心医院

替罗非班 急性ST段抬高型心肌梗死 经皮冠状动脉介入治疗 心肌灌注 心肌损伤

2024

中国实用医药
中国康复医学会

中国实用医药

影响因子:0.797
ISSN:1673-7555
年,卷(期):2024.19(1)
  • 15